Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association ( HFA ), European Society of Cardiology ( ESC )
Year: 2021
Type: review
Abstract: New biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the most promising emerging candidates for clinical assessment and management of patients with heart failure. We discuss high-sensitivity cardiac troponins (Tn), procalcitonin, novel kidney markers, soluble suppression of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor-15 (GDF-15), cluster of differentiation 146 (CD146), neprilysin, adrenomedullin (ADM), and also discuss proteomics and genetic-based risk scores. We focused on guidance and assistance with daily clinical care decision-making. For each biomarker, analytical considerations are discussed, as well as performance regarding diagnosis and prognosis. Furthermore, we discuss potential implementation in clinical algorithms and in ongoing clinical trials.
DOI: 10.1002/ejhf.2346
Institutions: University Medical Center Groningen, Universitat Autònoma de Barcelona, Centro de Investigación en Red en Enfermedades Cardiovasculares, Hospital Universitari Germans Trias i Pujol, Inserm, Université Paris Cité, Hôpital Lariboisière, Hôpital Saint-Louis, Marqueurs cardiovasculaires en situation de stress, Medizinische Hochschule Hannover, Imperial College London, University of Glasgow, University of Warwick, Monash University, Massachusetts General Hospital, University of California San Diego, St. Vincent's University Hospital, Ospedale di Bolzano, National University of Singapore, Serbian Academy of Sciences and Arts, University of Belgrade, University of Basel, University Hospital of Basel
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Keywords: heart failure, circulating biomarkers, natriuretic peptides, high-sensitivity troponin, procalcitonin, kidney injury biomarkers, soluble ST2, galectin-3, growth differentiation factor 15, CD146, neprilysin, adrenomedullin, proteomics, polygenic risk score, diagnosis, prognosis, clinical decision-making, clinical algorithms
Open Access status: hybrid
Estimated APC paid: $4,700
Funders: National Science Foundation, Amgen, Pfizer, AstraZeneca, Universität Basel, Universitätsspital Basel, Impulse Dynamics, Abiomed, Fondation Leducq, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Schweizerische Herzstiftung, Universitair Medisch Centrum Groningen, Vifor Pharma, Servier, Stiftung für Kardiovaskuläre Forschung Basel, Sphingotec GmbH, Abbott Diagnostics, Respicardia, H2020 European Research Council
OpenAlex ID: W3197790635
